Tatiana Novobrantseva

Tatiana Novobrantseva is a Co-Founder and has served as Head of Research and Development of Verseau since its inception, she became Chief Scientific Officer in March 2019.

Before co-founding Verseau, Tatiana consulted for multiple companies on immunological aspects of drug development across different stages and therapeutic modalities in a variety of autoimmune, cancer, and rare disease indications. At her prior position as Director of Tumor Immunology at Jounce Therapeutics, Tatiana defined research plans for several programs at the company’s inception, as well as led a portfolio of programs on (re)activating the immune system against cancer.

Previously, Tatiana served as Associate Director at Alnylam Pharmaceuticals and Scientist II at Biogen. Tatiana’s scientific accomplishments include discovering the critical role for B cells in liver fibrosis, developing mechanistic insights for multiple therapeutic programs, pushing the envelope on siRNA delivery, and championing a dendritic cell cancer vaccine clinical program. Tatiana is an inventor on more than 22 patents and an author on more than 37 peer-reviewed manuscripts.

Tatiana completed her Ph.D. with Dr. Klaus Rajewsky at the University of Cologne in Germany, focusing on B cell development and function. She holds a diploma of engineer-physicist and an M.S. in molecular biology from the Moscow Institute of Physics and Technology.